Results for "Enzyme replacement therapy"
Conditions Encyclopedia Entry 1777920920
Cystic fibrosis (CF) is a chronic, genetic disorder that affects the respiratory, digestive, and reproductive systems, causing severe damage and often leading to premature death. ## Overview Cystic fibrosis is a complex and multifaceted condition that affects approximately 70,000 people worldwide. It is caused by a mutation in the **CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene**, which codes for a protein responsible for regulating the movement of salt and water in and out of cells. This mutation leads to the production of thick, sticky mucus that clogs the airways and digestive tract, causing a range of symptoms and complications. CF is an autosomal recessive disorder, meaning that a person must inherit two copies of the mutated gene (one from each parent) to develop the condition. Carriers of the mutated gene, who have one normal and one mutated copy, are generally asymptomatic but can pass the mutated gene to their offspring. The symptoms of CF can vary widely in severity and may include persistent coughing, wheezing, and shortness of breath, as well as digestive problems such as abdominal pain, diarrhea, and malnutrition. ## History/Background The first reported case of CF dates back to 1938, when Dr. William E. Ladd described a child with a condition characterized by "cystic fibrosis of the pancreas." However, it wasn't until the 1950s and 1960s that the condition began to be more widely recognized and studied. In 1972, the **CF Foundation** was established in the United States to raise awareness and funds for CF research. Since then, significant advances have been made in the diagnosis, treatment, and management of CF, including the development of **pulmonary function tests**, **genetic testing**, and **enzyme replacement therapy**. ## Key Information **Key Statistics:** - Prevalence: Approximately 70,000 people worldwide are affected by CF. - Incidence: The incidence of CF is estimated to be 1 in 2,500 to 1 in 3,500 live births. - Mortality: The median survival age for people with CF has increased significantly, from 5 years in the 1950s to 47 years in 2020. **Symptoms and Complications:** - Respiratory symptoms: persistent coughing, wheezing, and shortness of breath - Digestive symptoms: abdominal pain, diarrhea, and malnutrition - Reproductive symptoms: infertility, recurrent pregnancy loss - Other complications: **pneumonia**, **bronchiectasis**, **osteoporosis** **Treatment and Management:** - **Pulmonary function tests**: to monitor lung function and detect early signs of lung damage - **Genetic testing**: to diagnose CF and identify carriers - **Enzyme replacement therapy**: to replace deficient enzymes and improve digestive function - **Airway clearance techniques**: to remove mucus and improve lung function - **Nutritional support**: to ensure adequate nutrition and prevent malnutrition ## Significance Cystic fibrosis is a significant public health concern due to its high mortality rate and the impact it has on affected individuals and their families. The establishment of the CF Foundation and the development of new treatments and management strategies have improved the quality of life for people with CF and increased their life expectancy. However, more research is needed to develop effective treatments and a cure for CF. INFOBOX: - Name: Cystic Fibrosis - Type: Genetic disorder - Date: 1938 (first reported case) - Location: Worldwide - Known For: Chronic respiratory and digestive complications TAGS: Cystic Fibrosis, CF, Genetic disorder, Respiratory disease, Digestive disease, Reproductive disease, Pulmonary function tests, Enzyme replacement therapy, Airway clearance techniques.
Health & MedicineConditions Encyclopedia Entry 1778257099
** A rare genetic disorder characterized by an abnormal accumulation of **lysosomal** storage materials in cells, leading to cellular dysfunction and various systemic complications. **CONTENT** ### Overview **Conditions Encyclopedia Entry 1778257099**, also known as **Mucopolysaccharidosis Type II (MPS II)**, is a rare genetic disorder caused by the deficiency of the enzyme **iduronate-2-sulfatase (I2S)**. This enzyme plays a crucial role in breaking down **glycosaminoglycans (GAGs)**, which are complex carbohydrates found in connective tissue. Without sufficient I2S, GAGs accumulate in cells, leading to cellular dysfunction and various systemic complications. MPS II is a **lysosomal storage disorder**, which means that the abnormal accumulation of storage materials occurs within lysosomes, the cellular organelles responsible for breaking down and recycling cellular waste. This disorder is inherited in an **X-linked recessive** pattern, meaning that it primarily affects males, who have only one X chromosome. Females can be carriers of the mutated gene but are usually asymptomatic or mildly affected. The symptoms of MPS II can vary widely among affected individuals, but common features include developmental delays, **intellectual disability**, **cloudy corneas**, **hearing loss**, and **short stature**. Other complications may include **cardiovascular disease**, **respiratory problems**, and **skeletal abnormalities**. ### History/Background MPS II was first described in 1963 by French physicians Robert Neustein and Jean-Pierre Maroteaux. Since then, numerous studies have been conducted to understand the underlying mechanisms of the disorder and to develop effective treatments. In the 1980s, the first enzyme replacement therapy (ERT) was introduced, which involved administering the deficient enzyme, I2S, to affected individuals. However, this treatment was met with limited success due to the difficulty in delivering the enzyme to the lysosomes. In recent years, advances in gene therapy and ERT have led to the development of more effective treatments for MPS II. These treatments aim to restore the normal function of I2S and reduce the accumulation of GAGs in cells. ### Key Information - **Prevalence:** MPS II is a rare disorder, affecting approximately 1 in 100,000 to 1 in 250,000 individuals worldwide. - **Genetics:** MPS II is caused by mutations in the IDS gene, which encodes the I2S enzyme. - **Symptoms:** Common symptoms include developmental delays, intellectual disability, cloudy corneas, hearing loss, and short stature. - **Complications:** Cardiovascular disease, respiratory problems, and skeletal abnormalities are common complications. - **Treatment:** Enzyme replacement therapy and gene therapy are currently being explored as potential treatments for MPS II. ### Significance MPS II is a significant disorder due to its impact on affected individuals and their families. The disorder highlights the importance of early diagnosis and treatment, as well as the need for continued research into effective treatments. The development of gene therapy and ERT has provided new hope for individuals with MPS II, and ongoing research aims to improve these treatments and ultimately find a cure for this devastating disorder. **INFOBOX** - Name: Mucopolysaccharidosis Type II (MPS II) - Type: Genetic disorder - Date: 1963 (first described) - Location: Worldwide - Known For: Rare genetic disorder characterized by abnormal accumulation of lysosomal storage materials **TAGS:** Mucopolysaccharidosis, Lysosomal storage disorder, Genetic disorder, Enzyme replacement therapy, Gene therapy, Intellectual disability, Cloudy corneas, Hearing loss, Short stature.
Health & MedicineConditions Encyclopedia Entry 1777461665
** A rare genetic disorder characterized by the accumulation of **lysosomal storage** materials, leading to progressive damage to various organs and tissues. **CONTENT:** ## Overview **Conditions Encyclopedia Entry 1777461665**, also known as **Mucopolysaccharidosis Type II (MPS II)**, is a rare genetic disorder that affects approximately 1 in 25,000 to 1 in 50,000 individuals worldwide. It is a type of **lysosomal storage disease**, which occurs when the body is unable to break down and recycle certain **mucopolysaccharides** (complex carbohydrates). As a result, these substances accumulate in various organs and tissues, leading to progressive damage and a range of debilitating symptoms. MPS II is caused by a deficiency of the enzyme **iduronate-2-sulfatase**, which is responsible for breaking down **heparan sulfate** and **dermatan sulfate**. The disorder is inherited in an **X-linked recessive** pattern, meaning that it primarily affects males, who have only one X chromosome. Females can be carriers of the disorder, but they are less likely to develop symptoms due to the presence of a second X chromosome. ## History/Background The first reported case of MPS II dates back to 1963, when a group of researchers described a 6-year-old boy with a rare condition characterized by **clouded corneas**, **skeletal abnormalities**, and **mental retardation**. Since then, numerous studies have been conducted to better understand the underlying causes and mechanisms of the disorder. In the 1970s and 1980s, researchers identified the enzyme deficiency responsible for MPS II and developed diagnostic tests to detect the condition. ## Key Information MPS II is characterized by a range of symptoms, including: * **Clouded corneas** and **vision problems** * **Skeletal abnormalities**, such as **short stature** and **joint deformities** * **Mental retardation** and **behavioral problems** * **Respiratory problems**, including **pneumonia** and **bronchiectasis** * **Cardiovascular problems**, including **heart failure** and **arrhythmias** The symptoms of MPS II typically become apparent in early childhood, although some individuals may not develop noticeable symptoms until later in life. The disorder is progressive, meaning that it worsens over time, and there is currently no cure. However, various treatments and therapies can help manage the symptoms and improve the quality of life for individuals with MPS II. ## Significance MPS II is a rare but serious condition that affects individuals and families worldwide. Understanding the underlying causes and mechanisms of the disorder has led to the development of diagnostic tests and treatments, which can help improve the lives of those affected. Additionally, research into MPS II has contributed to our understanding of **lysosomal storage diseases** and the importance of **enzyme replacement therapy**. **INFOBOX:** - Name: Mucopolysaccharidosis Type II (MPS II) - Type: Genetic disorder - Date: 1963 (first reported case) - Location: Worldwide - Known For: Rare genetic disorder characterized by lysosomal storage material accumulation **TAGS:** Lysosomal storage disease, Mucopolysaccharidosis, MPS II, Iduronate-2-sulfatase, Heparan sulfate, Dermatan sulfate, X-linked recessive, Enzyme replacement therapy, Rare genetic disorder.